Amy is a managing partner in the New York office and focuses on investments in healthcare companies. She currently serves as executive chair of SQZ Biotech, as well as Lyndra Therapeutics, where she was co-founder and the company’s initial CEO. She also represents Polaris as a director of Cyclerion (NASDAQ: CYCN), DewPoint Therapeutics, Kallyope, and Volastra. She is also Director of Glympse.
Amy joined Polaris in 2014, at which time she assumed the role of CEO of Arsia Therapeutics, a Polaris-backed company later acquired by Eagle Pharmaceuticals. Prior to joining Polaris, Schulman was the general counsel of Pfizer, president of Pfizer Nutrition, and was instrumental in its sale to Nestle for $11.85 billion in 2012. Soon after, Schulman became the president of Pfizer Consumer Healthcare.
She is a Senior Lecturer at Harvard Business School and serves on the Boards of Directors of Alnylam Pharmaceuticals (NASDAQ: ALNY). She is a Phi Beta Kappa graduate of Wesleyan University and earned her J.D. from Yale Law School.